5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 10.96▲ | 10.95▲ | 10.93▲ | 10.86▲ | 10.93▲ |
MA10 | 10.93▲ | 10.93▲ | 10.86▲ | 10.71▲ | 10.90▲ |
MA20 | 10.95▲ | 10.85▲ | 10.89▲ | 10.98▲ | 10.88▲ |
MA50 | 10.92▲ | 10.87▲ | 10.67▲ | 10.94▲ | 10.56▲ |
MA100 | 10.85▲ | 10.67▲ | 10.89▲ | 10.79▲ | 8.31▲ |
MA200 | 10.86▲ | 10.95▲ | 10.72▲ | 10.64▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.004▲ | 0.012▲ | 0.000▲ | 0.001▲ | -0.031▼ |
RSI | 59.080▲ | 58.414▲ | 60.070▲ | 53.316▲ | 52.469▲ |
STOCH | 77.456 | 73.117 | 79.143 | 58.801 | 47.187 |
WILL %R | -8.696▲ | -14.815▲ | -12.381▲ | -48.746 | -44.156 |
CCI | 114.952▲ | 101.064▲ | 80.420 | 32.820 | -2.153 |
Thursday, April 25, 2024 09:55 AM
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...
|
Wednesday, April 24, 2024 09:59 PM
2024--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced ...
|
Wednesday, April 24, 2024 09:43 AM
David Einhorn's Greenlight takes a stake in HP Inc., causing the stock to rise 1.2%. Einhorn sees potential in HP's AI capabilities.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 10.95 | 11.02 | 10.875 | 10.98 | 1,066,212 |
25/04/24 | 10.78 | 10.91 | 10.514 | 10.88 | 3,719,731 |
24/04/24 | 10.93 | 11.05 | 10.785 | 10.90 | 2,837,387 |
23/04/24 | 10.65 | 11.05 | 10.605 | 10.94 | 4,978,898 |
22/04/24 | 10.52 | 10.815 | 10.3608 | 10.60 | 5,323,946 |
19/04/24 | 10.30 | 10.48 | 10.265 | 10.46 | 4,664,389 |
18/04/24 | 10.40 | 10.50 | 10.325 | 10.36 | 3,419,753 |
17/04/24 | 10.76 | 10.80 | 10.42 | 10.44 | 4,076,241 |
16/04/24 | 10.77 | 10.915 | 10.635 | 10.71 | 4,731,756 |
15/04/24 | 10.98 | 11.045 | 10.81 | 10.84 | 5,009,268 |
|
|
||||
|
|
||||
|
|